These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 15706458)

  • 21. A unique natural selective kappa-opioid receptor agonist, salvinorin A, and its roles in human therapeutics.
    Cruz A; Domingos S; Gallardo E; Martinho A
    Phytochemistry; 2017 May; 137():9-14. PubMed ID: 28190678
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DNA identification of Salvia divinorum samples.
    Murphy TM; Bola G
    Forensic Sci Int Genet; 2013 Jan; 7(1):189-93. PubMed ID: 22578875
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulating a novel drug: an evaluation of changes in use of Salvia divinorum in the first year of Florida's ban.
    Stogner J; Khey DN; Griffin OH; Miller BL; Boman JH
    Int J Drug Policy; 2012 Nov; 23(6):512-21. PubMed ID: 22502947
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Salvia divinorum: An overview of the usage, misuse, and addiction processes.
    Mahendran R; Lim HA; Tan JY; Chua SM; Winslow M
    Asia Pac Psychiatry; 2016 Mar; 8(1):23-31. PubMed ID: 26617400
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Salvinorin A: from natural product to human therapeutics.
    Vortherms TA; Roth BL
    Mol Interv; 2006 Oct; 6(5):257-65. PubMed ID: 17035666
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pattern of use and subjective effects of Salvia divinorum among recreational users.
    González D; Riba J; Bouso JC; Gómez-Jarabo G; Barbanoj MJ
    Drug Alcohol Depend; 2006 Nov; 85(2):157-62. PubMed ID: 16720081
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selective natural kappa opioid and cannabinoid receptor agonists with a potential role in the treatment of gastrointestinal dysfunction.
    Fichna J; Schicho R; Janecka A; Zjawiony JK; Storr M
    Drug News Perspect; 2009 Sep; 22(7):383-92. PubMed ID: 19890495
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum.
    Johnson MW; MacLean KA; Reissig CJ; Prisinzano TE; Griffiths RR
    Drug Alcohol Depend; 2011 May; 115(1-2):150-5. PubMed ID: 21131142
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Authentication and ultra performance liquid chromatography (UPLC)/MS analysis of magic mint, Salvia divinorum and its related plants].
    Maruyama T; Kamakura H; Kikura-Hanajiri R; Goda Y
    Yakugaku Zasshi; 2008 Jan; 128(1):179-83. PubMed ID: 18176071
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Opioid receptors and legal highs: Salvia divinorum and Kratom.
    Babu KM; McCurdy CR; Boyer EW
    Clin Toxicol (Phila); 2008 Feb; 46(2):146-52. PubMed ID: 18259963
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel use patterns of Salvia divinorum: unobtrusive observation using YouTube™.
    Casselman I; Heinrich M
    J Ethnopharmacol; 2011 Dec; 138(3):662-7. PubMed ID: 21843613
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Salvia divinorum: toxicological aspects and analysis in human biological specimens.
    Margalho C; Corte-Real F; López-Rivadulla M; Gallardo E
    Bioanalysis; 2016 Jul; 8(13):1415-25. PubMed ID: 27277872
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin A.
    Cunningham CW; Rothman RB; Prisinzano TE
    Pharmacol Rev; 2011 Jun; 63(2):316-47. PubMed ID: 21444610
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantification of the plant-derived hallucinogen Salvinorin A in conventional and non-conventional biological fluids by gas chromatography/mass spectrometry after Salvia divinorum smoking.
    Pichini S; Abanades S; Farré M; Pellegrini M; Marchei E; Pacifici R; Torre Rde L; Zuccaro P
    Rapid Commun Mass Spectrom; 2005; 19(12):1649-56. PubMed ID: 15915477
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Salvia divinorum and salvinorin A: an update on pharmacology and analytical methodology.
    Grundmann O; Phipps SM; Zadezensky I; Butterweck V
    Planta Med; 2007 Aug; 73(10):1039-46. PubMed ID: 17628834
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Forensic analysis of Salvia divinorum using multivariate statistical procedures. Part I: discrimination from related Salvia species.
    Willard MA; McGuffin VL; Smith RW
    Anal Bioanal Chem; 2012 Jan; 402(2):833-42. PubMed ID: 22038586
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Legally tripping: a qualitative profile of Salvia divinorum use among young adults.
    Kelly BC
    J Psychoactive Drugs; 2011; 43(1):46-54. PubMed ID: 21615007
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Salvinorin C, a new neoclerodane diterpene from a bioactive fraction of the hallucinogenic Mexican mint Salvia divinorum.
    Valdés LJ; Chang HM; Visger DC; Koreeda M
    Org Lett; 2001 Nov; 3(24):3935-7. PubMed ID: 11720573
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthetic studies of neoclerodane diterpenes from Salvia divinorum: semisynthesis of salvinicins A and B and other chemical transformations of salvinorin A.
    Harding WW; Schmidt M; Tidgewell K; Kannan P; Holden KG; Gilmour B; Navarro H; Rothman RB; Prisinzano TE
    J Nat Prod; 2006 Jan; 69(1):107-12. PubMed ID: 16441078
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Salvia divinorum.
    Meyer EG; Writer BW
    Psychosomatics; 2012; 53(3):277-9. PubMed ID: 22289631
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.